Patricia Pautier, MD, on Leiomyosarcoma: Doxorubicin and Trabectedin for First-Line Treatment

June 23, 2020 By The ASCO Post Staff

Patricia Pautier, MD, of Institut Gustave Roussy, discusses final results of the phase II LMS-02 study, which showed the combination of doxorubicin and trabectedin to be an effective first-line therapy for patients with leiomyosarcoma, with an acceptable safety profile (Abstract 11506).

Related Content